Jim Cramer: This Health Care Stock Is 'Very, Very Speculative'

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Merus N.V. MRUS is still “very, very speculative.”

On Wednesday, Merus announced the FDA approval of BIZENGRI for NRG1+ pancreatic adenocarcinoma and NRG1+ non–small cell lung cancer based on safety and efficacy data from the eNRGy study.

“Storied company, terrific. It does great,” Cramer said when asked about Allison Transmission Holdings, Inc. ALSN. “I actually would prefer you to swap out right now and go to be with Mary Barra at GM GM. Cheaper and will be just as good.”

On Oct.29, Allison Transmission reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance.

NANO Nuclear Energy Inc. NNE has “no earnings,” Cramer said. “I want you to take out almost all of your cost basis and let the rest run.”

On Dec. 4, the company earlier announced a Memorandum of Understanding (MOU) with the U.S. Department of Energy's Idaho Operations Office to explore siting, construction and operation of its proprietary ‘ZEUS’ and ‘ODIN’ microreactors at the Idaho National Laboratory (INL).

“It is living off, I think, a lot of the federal money that's been spent. So, I don't want to get greedy,” Cramer said when asked about Sterling Infrastructure, Inc. STRL. He recommended taking some off the table and let the rest run.

On Nov. 6, Sterling Infrastructure reported worse-than-expected third-quarter revenue results and lowered the top end of its FY24 revenue guidance.

Price Action:

• Allison Transmission shares gained 0.9% to settle at $117.95 on Wednesday.
• Nano Nuclear Energy shares fell 0.5% to close at $26.50.
• Sterling Infrastructure shares gained 1.7% to close at $198.82 on Wednesday.
• Merus shares fell 1.6% to settle at $45.49 during the session.

Read Next:

• Top 3 Tech And Telecom Stocks That May Implode This Quarter

Image: Shutterstock